GALT vs. GLSI, ALIM, RIGL, LFCR, GOSS, TELO, CAPR, PRLD, ACRV, and SCPH
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Greenwich LifeSciences (GLSI), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), Telomir Pharmaceuticals (TELO), Capricor Therapeutics (CAPR), Prelude Therapeutics (PRLD), Acrivon Therapeutics (ACRV), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical preparations" industry.
Galectin Therapeutics (NASDAQ:GALT) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
Galectin Therapeutics received 340 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 60.21% of users gave Galectin Therapeutics an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 239.51%. Greenwich LifeSciences has a consensus target price of $36.00, suggesting a potential upside of 171.08%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Greenwich LifeSciences.
Galectin Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Galectin Therapeutics' return on equity of 0.00% beat Greenwich LifeSciences' return on equity.
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Galectin Therapeutics had 6 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 7 mentions for Galectin Therapeutics and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.59 beat Galectin Therapeutics' score of -1.04 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Galectin Therapeutics beats Greenwich LifeSciences on 7 of the 13 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
